Abbott Laboratories (ABT)
Abbott recalls glucose sensors after seven deaths linked to faulty readings
Abbott has recalled certain glucose monitoring sensors after reports linked the devices to seven deaths and 860 serious injuries, the U.S. health regulator said on Wednesday.
5 Goldman Sachs Top Stock Picks Have Huge Upside Potential and Pay Dividends
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and ranks 55th on the Fortune 500 list of the largest U.S.
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors
In reality, Abbott Laboratories is actually a Dividend Aristocrat – a vaunted status reserved for companies that have increased dividends for at least 25 consecutive years. ABT grew its revenue from $20.8 billion in FY 2016 to $44.3 billion in FY 2025. That's a compound annual growth rate of 8.8%. Abbott Laboratories has a great financial position. The long-term debt/equity ratio is 0.3, while the interest coverage ratio is 17.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy
Abbott Laboratories is rated 'Buy,' following a recent price drop, driven by Nutrition segment weakness and COVID-19 diagnostics decline. ABT's Medical Devices segment, especially CGM, continues to deliver robust double-digit growth, offsetting Nutrition softness. Management guides for 7% sales and 10% EPS growth in 2025, underpinned by innovation and normalization in Nutrition.
Is Abbott's January Pullback a Good Time to Buy?
Abbott Laboratories' NYSE: ABT January 2026 price pullback is making its stock look attractively valued. The move, driven more by market angst and fear than by any real weaknesses, seems to be a knee-jerk overreaction that has launched the stock back into the buy zone.
Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity
Abbott Laboratories experienced a post-earnings sell-off driven by weakness in its Nutrition segment and a sizable revenue miss. Despite segment headwinds, ABT delivered double-digit bottom-line growth, margin expansion, and raised its dividend by 7%, reinforcing its Dividend King status. Management guides for 2026 EPS of $5.55-$5.80 and 6.5%-7.5% sales growth, with innovation and cost initiatives expected to offset ongoing challenges.
Abbott (ABT) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is The Fall In Abbott Stock Justified?
Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, aligning with expectations, while the total annual adjusted EPS reached $5.15, indicating a 10% growth.
Abbott Laboratories: Buy This Dividend King On Sale Now
Last month, Abbott Laboratories hiked its dividend for the 54th consecutive year. The company's FreeStyle Libre and Volt PFA System franchises, as well as its pending acquisition of Exact Sciences, position it for strong growth. Abbott Laboratories boasts a vigorous interest coverage ratio.
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
